Exelixis, Inc. announced today that Michael Morrissey, PhD, the company’s president and chief executive officer, will present at two upcoming investor conferences.
Morgan Stanley Global Healthcare Conference: Exelixis’ presentation will take place at 10:20 a.m. EDT on Tuesday, September 13, 2011, in New York.
UBS Global Life Sciences Conference: Exelixis’ presentation will take place at 8:30 a.m. EDT on Monday, September 19, 2011, in New York.
During each presentation, Dr. Morrissey will provide a general business update, review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer, and discuss the pivotal trial plans and regulatory strategy for the compound.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs.